Intelligence Driven Advisers LLC Sells 755 Shares of DexCom, Inc. (NASDAQ:DXCM)

Intelligence Driven Advisers LLC lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 5,237 shares of the medical device company’s stock after selling 755 shares during the period. Intelligence Driven Advisers LLC’s holdings in DexCom were worth $636,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Stableford Capital II LLC raised its position in shares of DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after buying an additional 88 shares during the last quarter. Valley National Advisers Inc. raised its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares in the last quarter. FORVIS Wealth Advisors LLC lifted its position in shares of DexCom by 0.7% in the 4th quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after acquiring an additional 110 shares during the period. Cary Street Partners Investment Advisory LLC grew its holdings in shares of DexCom by 11.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after purchasing an additional 115 shares in the last quarter. Finally, HM Payson & Co. increased its position in shares of DexCom by 8.5% during the third quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock valued at $138,000 after purchasing an additional 116 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the sale, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the transaction, the executive vice president now directly owns 68,682 shares in the company, valued at approximately $9,618,227.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sadie Stern sold 20,321 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the transaction, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock valued at $25,530,859 in the last three months. Corporate insiders own 0.41% of the company’s stock.

DexCom Price Performance

DXCM stock traded up $0.33 during midday trading on Thursday, reaching $126.21. 1,104,152 shares of the company’s stock traded hands, compared to its average volume of 3,031,521. The company has a 50-day simple moving average of $131.68 and a two-hundred day simple moving average of $119.57. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The company has a market cap of $50.19 billion, a price-to-earnings ratio of 80.84, a PEG ratio of 2.18 and a beta of 1.23. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. On average, analysts anticipate that DexCom, Inc. will post 1.77 earnings per share for the current year.

Wall Street Analyst Weigh In

DXCM has been the subject of several research reports. Raymond James raised their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Canaccord Genuity Group lifted their target price on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Royal Bank of Canada began coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, UBS Group upped their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.